Recbio First Biotech To Brave A Hong Kong IPO In 2022

mRNA Contender For Omicron?

 
• By Dexter Jie Yan

Chinese vaccine maker Recbio hopes an IPO in Hong Kong will bring investor attention to its mRNA COVID vaccine with potential against the Omicron variant.

Stock Exchange STAR Market
Recbio’s IPO filing notable given share falls for Hong Kong-listed biotechs • Source: Alamy

More from China

More from Focus On Asia